Search Result
Results for "
cleavable?linker
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-145735
-
-
-
- HY-129365
-
|
|
ADC Linker
|
Cancer
|
|
SNPB is a cleavable linker that is used for making antibody-drug conjugate (ADC).
|
-
-
- HY-126498
-
|
|
ADC Linker
|
Cancer
|
|
PDEC-NB is a disulfide cleavable linker used for the antibody-drug conjugate (ADC).
|
-
-
- HY-44235
-
|
|
ADC Linker
|
Cancer
|
|
MC-Gly-Gly-Phe is a cleavable linker used for antibody-drug conjugates (ADC).
|
-
-
- HY-126530
-
-
-
- HY-160247
-
|
|
Drug-Linker Conjugates for ADC
|
Others
|
|
Boc-Lys-PEG8-N-bis(D-glucose) (compound 89-5) is a drug linker that can be used in the synthesis of antibody-drug conjugates (ADCs) extracted from patent WO2023280227A2 .
|
-
-
- HY-W098764
-
|
|
ADC Linker
|
Others
|
|
Allyl (2-aminoethyl)carbamate hydrochloride is a cleavable linker.
|
-
-
- HY-129376
-
|
|
ADC Linker
|
Cancer
|
|
Sulfo-SNPB is a cleavable linker that is used for making antibody-drug conjugate (ADC).
|
-
-
- HY-126519
-
|
|
ADC Linker
|
Cancer
|
|
PDdEC-NB is a disulfide cleavable linker used for the antibody-drug conjugate (ADC).
|
-
-
- HY-129375
-
|
|
ADC Linker
|
Cancer
|
|
SNPB-sulfo-Me is a cleavable linker that is used for making antibody-drug conjugate (ADC).
|
-
-
- HY-19318A
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-D-Val-Cit-PAB is a cleavable linker for antibody-agent-conjugation (ADC) .
|
-
-
- HY-19318B
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-D-Val-Cit-PAB is a cleavable linker for antibody-agent-conjugation (ADC) .
|
-
-
- HY-153180
-
-
-
- HY-153947
-
-
-
- HY-128929
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-PEA (Example 1-2) is a used as a cleavable linker for antibody-drug conjugates (ADC) .
|
-
-
- HY-129352
-
|
|
ADC Linker
|
Cancer
|
|
Cbz-Phe-(Alloc)Lys-PAB-PNP is an cleavable linker for antibody-drug conjugates (ADC) design.
|
-
-
- HY-129367
-
|
|
ADC Linker
|
Cancer
|
|
NO2-SPP is a cleavable linker that is used for making antibody-drug conjugate (ADC).
|
-
-
- HY-129353
-
|
|
ADC Linker
|
Cancer
|
|
Boc-Phe-(Alloc)Lys-PAB-PNP is a used as a cleavable linker for antibody-drug conjugates (ADC).
|
-
-
- HY-19318C
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-D-Val-D-Cit-PAB is a cleavable linker for antibody-agent-conjugation (ADC) .
|
-
-
- HY-44235A
-
|
|
ADC Linker
|
Cancer
|
|
MC-Gly-Gly-D-Phe is a cleavable linker used for sythesis of antibody-drug conjugates (ADC).
|
-
-
- HY-128940
-
|
|
ADC Linker
|
Cancer
|
|
EC089 is a cleavable linker used in conjugates of tubulysins and folates, and extracted from patent WO2011069116A1 .
|
-
-
- HY-400191
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-Gly-(d-Gly)-allyl propionate is a cleavable linker that can be used to synthesize Antibody-Drug Conjugates (ADCs).
|
-
-
- HY-129378
-
|
|
ADC Linker
|
Cancer
|
|
NO2-SPP-sulfo-Me is a cleavable linker that is used for making antibody-drug conjugate (ADC) .
|
-
-
- HY-W011561
-
|
|
ADC Linker
|
Cancer
|
|
Boc-NH-C6-Br is a non-cleavable linker used for antibody-drug conjugates (ADC) .
|
-
-
- HY-400356
-
|
|
ADC Linker
|
Cancer
|
|
Glucocorticoid receptor agonist-1 phosphate Gly-Glu (TFA) is a cleavable linker, that can be used to synthesize Antibody-Drug Conjugates (ADCs).
|
-
-
- HY-44980
-
|
|
ADC Linker
|
Others
|
|
Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).
|
-
-
- HY-141153
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB-PNP is a cleavable linker for synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-P1449
-
|
|
ADC Linker
|
Cancer
|
|
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).
|
-
-
- HY-P1449A
-
|
|
ADC Linker
|
Cancer
|
|
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).
|
-
-
- HY-101162
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SGD-1910 is a agent-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala .
|
-
-
- HY-P99593
-
|
DMUC5754A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .
|
-
-
- HY-128954
-
-
-
- HY-20336
-
|
Maleimidocaproyl-L-valine-L-citrulline-p-aminobenzyl alcohol p-nitrophenyl carbonate
|
ADC Linker
|
Others
Inflammation/Immunology
Cancer
|
|
Mc-Val-Cit-PABC-PNP is a cathepsin cleavable linker for antibody-drug conjugates (ADCs) which couples the antibody element to the effecting compound. Mc-Val-Cit-PABC-PNP can be used in the synthesis of ADCs .
|
-
-
- HY-126681
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SC-VC-PAB-MMAE is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB .
|
-
-
- HY-41189
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Val-Cit-PAB-PNP has superior plasma stability comparable to that of non-cleavable linkers .
|
-
-
- HY-111554
-
-
-
- HY-P99101
-
|
AEX-4089
|
ADC Antibody
|
Cancer
|
|
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. .
|
-
-
- HY-P99734
-
|
ADCT-601
|
TAM Receptor
|
Cancer
|
|
Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers .
|
-
-
- HY-P99593A
-
|
DMUC5754A (solution)
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker .
|
-
-
- HY-145674
-
|
|
Others
|
Cancer
|
|
HDP 30.1699, the derivative of α-Amanitin, shows considerable cross-links. The cysteine residues of the anti-HER2 THIOMAB antibody are used for conjugation of the cysteine reactive linker–Amanitin compound, HDP 30.1699, with a cleavable linker by maleimide chemistry .
|
-
-
- HY-126350
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
CL2-SN-38 is a cleavable linker-based agent-Linker conjugate, it can conjugate with the anti-Trop-2-humanized antibody hRS7. CL2-SN-38 can be used for the reasearch of cancer .
|
-
-
- HY-P9985
-
|
RC48
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity .
|
-
-
- HY-151944
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Antibacterial agent 128 is a siderophore analog-Ciprofloxacin (Ciprofloxacin (HY-B0356)) conjugate with a cleavable linker. Antibacterial agent 128 shows antibiotic activities against P. aeruginosa (MIC values of 0.25-64 μg/mL) and B. pseudomallei (MIC values of 1-32 μg/mL) .
|
-
-
- HY-111555
-
-
-
- HY-P9988
-
|
BA301
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .
|
-
-
- HY-44980G
-
|
|
ADC Linker
|
Others
|
|
Fmoc-Gly-NH-CH2-acetyloxy GMP is a GMP grade Fmoc-Gly-NH-CH2-acetyloxy (HY-44980). Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).
|
-
-
- HY-P99813
-
|
HER3-DXd; U3-1402
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
|
-
-
- HY-115524
-
|
|
ADC Linker
|
Cancer
|
|
DBCO-NHS ester 2 is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 2 is a derivative of Dibenzylcyclooctyne (DBCO) used in copper-free click chemistry . DBCO-NHS ester 2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
-
- HY-P99542
-
|
SAR-408701; HuMAb2-3-SPDB-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
|
-
-
- HY-164310
-
|
|
Microtubule/Tubulin
Drug-Linker Conjugates for ADC
|
Cancer
|
|
TCO-PEG3-Glu-Val-Cit-PABC-MMAF is a linker-drug conjugate, which is consisted of a click pair TCO, a spacer PEG, a cleavable linker Glu-Val-Cit, a PBAC group and a cytotoxin MMAF (HY-15579). TCO-PEG3-Glu-Val-Cit-PABC-MMAF can be used for synthesis of dual drug ADC .
|
-
- HY-133492
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DBCO-PEG4-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4. DBCO-PEG4-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-115545
-
|
|
ADC Linker
|
Cancer
|
|
DBCO-NHS ester 3 (Compound 12) is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 3 is a derivative of Dibenzylcyclooctyne (DBCO) obtained by activation of N-hydroxysuccinimide by the carboxylic acid moiety of both methyl-oxanorbornadiene (MeOND) and dibenzoazacyclooctyne (DIBAC) . DBCO-NHS ester 3 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-P99683
-
|
SGN-LIV1A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .
|
-
- HY-157813
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan is a drug-linker conjugates for ADC, consiting of a cleavable linker and Exatecan (HY-13631). 2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan can be linked to anti-Her3 antibody .
|
-
- HY-164762
-
|
SHR-A1811
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .
|
-
- HY-164761
-
|
|
Antibody-Drug Conjugates (ADCs)
CD22
|
Cancer
|
|
Anti-CD22-NMS249 is a CD22-targeting antibody-drug conjugate (ADC). Anti-CD22-NMS249 is composed of a humanized anti-CD22 antibody Pinatuzumab (HY-P99230), a cleavable linker (Mc-VC-PAB), and a DNA topoisomerase II inhibitor payload PNU-159682 (HY-16700). Anti-CD22-NMS249 can be used for research in non-Hodgkin lymphoma (NHL) .
|
-
- HY-W190943
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-131088
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-145736A
-
|
|
Drug-Linker Conjugates for ADC
Apoptosis
|
Cancer
|
|
β-Glucuronide-dPBD-PEG5-NH2 TFA is the β-glucuronide-linked pyrrolobenzodiazepine dimer, which binds to the prenylated antibody for synthesis of antibody-drug conjugate (ADC) cIRCR201-dPBD.β-glucuronide-linkage as a cleavable linker. β-Glucuronide-dPBD-PEG5-NH2 TFA, as a proagent of cIRCR201-dPBD, reduces side effects. β-Glucuronide-dPBD-PEG5-NH2 TFA can induce apoptosis and arrest cell cycle. β-Glucuronide-dPBD-PEG5-NH2 TFA has antitumor activity .
|
-
- HY-145736
-
|
|
Drug-Linker Conjugates for ADC
Apoptosis
|
Cancer
|
|
β-Glucuronide-dPBD-PEG5-NH2 is the β-glucuronide-linked pyrrolobenzodiazepine dimer, which binds to the prenylated antibody for synthesis of antibody-drug conjugate (ADC) cIRCR201-dPBD. β-glucuronide-linkage as a cleavable linker. β-Glucuronide-dPBD-PEG5-NH2, as a proagent of cIRCR201-dPBD, reduces side effects. β-Glucuronide-dPBD-PEG5-NH2 can induce apoptosis and arrest cell cycle. β-Glucuronide-dPBD-PEG5-NH2 has antitumor activity .
|
-
- HY-153360
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-44980G
-
|
|
Fluorescent Dye
|
|
Fmoc-Gly-NH-CH2-acetyloxy GMP is a GMP grade Fmoc-Gly-NH-CH2-acetyloxy (HY-44980). Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).
|
| Cat. No. |
Product Name |
Type |
-
- HY-44980G
-
|
|
Biochemical Assay Reagents
|
|
Fmoc-Gly-NH-CH2-acetyloxy GMP is a GMP grade Fmoc-Gly-NH-CH2-acetyloxy (HY-44980). Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1449
-
|
|
ADC Linker
|
Cancer
|
|
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).
|
-
- HY-P1449A
-
|
|
ADC Linker
|
Cancer
|
|
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).
|
-
- HY-P4139
-
|
|
Peptides
|
Others
|
|
activable cell-penetrating peptide (ACCP) consists of a polycationic CPP (typically arg9 or r9) connected via a cleavable linker to a matching polyanion (typically glu9 or e9), which reduces the net charge to nearly zero and thereby inhibits adhesion and uptake into cells .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99593
-
|
DMUC5754A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .
|
-
- HY-P99101
-
|
AEX-4089
|
ADC Antibody
|
Cancer
|
|
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. .
|
-
- HY-P99813
-
|
HER3-DXd; U3-1402
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
|
-
- HY-P99542
-
|
SAR-408701; HuMAb2-3-SPDB-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
|
-
- HY-P99734
-
|
ADCT-601
|
TAM Receptor
|
Cancer
|
|
Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers .
|
-
- HY-P99593A
-
|
DMUC5754A (solution)
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker .
|
-
- HY-P9988
-
|
BA301
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .
|
-
- HY-P99683
-
|
SGN-LIV1A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
|
Classification |
-
- HY-115524
-
|
|
|
DBCO
ADC Synthesis
|
|
DBCO-NHS ester 2 is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 2 is a derivative of Dibenzylcyclooctyne (DBCO) used in copper-free click chemistry . DBCO-NHS ester 2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-133492
-
|
|
|
DBCO
|
|
DBCO-PEG4-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4. DBCO-PEG4-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-W190943
-
|
|
|
Azide
|
|
Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-115545
-
|
|
|
DBCO
ADC Synthesis
|
|
DBCO-NHS ester 3 (Compound 12) is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 3 is a derivative of Dibenzylcyclooctyne (DBCO) obtained by activation of N-hydroxysuccinimide by the carboxylic acid moiety of both methyl-oxanorbornadiene (MeOND) and dibenzoazacyclooctyne (DIBAC) . DBCO-NHS ester 3 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-131088
-
|
|
|
Azide
|
|
N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-21242
-
|
|
|
Nucleoside Phosphoramidites
|
|
MMT-Hexylaminolinker Phosphoramidite is a cleavable linker. MMT-Hexylaminolinker Phosphoramidite can be used to syntheses oligonucleotide gapmers or other nucleic acid molecules .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
